SANTA FE, N.M., Dec. 10 /PRNewswire/ -- Bioreason, Inc., a leading supplier of software solutions for rapid, in-depth analysis of drug discovery screening and optimization data, announced today the extension of its Material Transfer Agreement (MTA) with the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) for a period of one year. Under the agreement, the FDA will have limited access to the ClassPharmer technology in exchange for the use of certain toxicity data. In addition, the long-term objectives described in the agreement include the collaborative development of a human toxicology prediction solution that incorporates non-proprietary FDA data and predictive models from multiple sources. The ultimate goal is to improve the design of drugs with acceptable pharmaceutical qualities and to enhance the drug approval process.
"We are very happy that the FDA has been pleased with the results of the initial proof of concept work with Bioreason," commented Terry Brunck, Ph.D., Vice President of Research and Development. "The company is excited at the opportunity to expand this into a longer term collaborative relationship."
The ClassPharmer(TM) Suite of software products provides an automated mechanism for learning structure-based classes from screening data that can then be used in a variety of applications. This class-based approach enables the user to easily generate high quality queries and quickly derive conclusions that can be consistently communicated in an intuitive manner throughout the discovery process.
Bioreason, Inc., is headquartered in Santa Fe, New Mexico, with sales and support offices in Strasbourg (France) and Michigan, and with sales and support representation in Tokyo. Bioreason provides knowledge-based software, services, and collaborations that automate reasoning with complex data in the drug discovery process. For information on the company, see http://www.bioreason.com/ .
CONTACT: Patricia Bacha, Senior Scientist of Bioreason, Inc.,+1-505-995-8188